Nanobiotix S.A. (NBTX)

Nasdaq: NBTX · Pharmaceutical Preparations · Paris, FR · filing with the SEC since 2018

Grade5.8

◀ Past 5.6● Present 5.4▶ Future 6.6

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

Income statement, as filed

In thousands of euros (EUR), as filed; per-share figures in euros; share counts. The fiscal year ends in December.

Income statement, by fiscal year, newest first
Fiscal year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Report filed	Mar 31, 2026	Apr 2, 2025	Apr 24, 2024	Apr 24, 2023	Apr 8, 2022	Apr 7, 2021	·	·
Revenue	32,593	-7,191	36,207	4,776	2,647	2,512	2,541	3,479
For lenders
Net interest income	-10,265	-7,916	-7,779	-5,599	-383	4,676	-4,434	·
Research and development	23,115	40,541	38,396	32,636	30,378	24,330	30,411	20,893
Selling, general and administrative	20,360	20,527	22,049	17,857	19,434	14,611	18,909	12,653
Total operating expenses	43,411	61,202	62,986	51,478	55,226	38,941	49,320	33,546
Operating income	-10,818	-68,392	-26,779	-46,702	-52,579	-36,428	-46,779	-30,067
Finance costs	15,233	7,488	14,803	13,863	780	-2,646	4,970	1,449
Finance income	2,092	7,849	2,002	3,533	6,360	201	837	1,172
Net finance income (costs)	-13,141	361	-12,801	-10,329	5,580	2,847	-4,133	-277
Income before income taxes	-23,961	-68,132	-39,700	-57,041	-47,003	-33,590	-50,915	-30,345
Income tax expense	3	101	120	10	5	9	3	0
Net income	-23,961	-68,132	-39,700	-57,000^r	-47,003	-33,590	-50,915	-30,345
Net income to shareholders	-23,961	-68,132	-39,700	-57,041	-47,063	-33,590	-50,915	-30,345
Earnings per share, basic	-0.50	-1.44	-1.08	-1.64	-1.35	-1.38	-2.35	-1.55
Earnings per share, diluted	-0.50	-1.44	-1.08	-1.64	-1.35	-1.38	-2.35	-1.55
Weighted average shares, basic	47,819,627^b	47,265,189^b	36,928,161^b	34,851,868^b	34,733,418^b	24,385,827^b	21,631,514^b	19,633,373^b

As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. ^r restated by the company in a later report; ^b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.

What each line is, and the XBRL concept behind it

Revenue what customers paid for what it soldifrs-full:Revenue

Net interest income interest earned less interest paidifrs-full:InterestRevenueExpense

Research and development spent on inventing what it sells nextifrs-full:ResearchAndDevelopmentExpense

Selling, general and administrative the cost of selling and of running the companyifrs-full:SellingGeneralAndAdministrativeExpense

Total operating expenses the running costs togetherifrs-full:OperatingExpense

Operating income profit from running the business, before interest and taxifrs-full:ProfitLossFromOperatingActivities

Finance costs what its borrowing costifrs-full:FinanceCosts

Finance income what its cash and investments earnedifrs-full:FinanceIncome

Net finance income (costs) interest earned less interest paid, outside the businessifrs-full:FinanceIncomeCost

Income before income taxes profit before taxifrs-full:ProfitLossBeforeTax

Income tax expense tax charged on the period's profitifrs-full:IncomeTaxExpenseContinuingOperations

Net income the whole group's profit, minority holders' share includedifrs-full:ProfitLoss

Net income to shareholders the profit or loss that belongs to the company's shareholdersifrs-full:ProfitLossAttributableToOwnersOfParent

Earnings per share, basic net income per share outstandingifrs-full:BasicEarningsLossPerShare

Earnings per share, diluted net income per share, counting every share that could be issuedifrs-full:DilutedEarningsLossPerShare

Weighted average shares, basic the average count of shares outstandingifrs-full:WeightedAverageShares

SI Assistanton NBTX · research, not advice